Alberto Bergareche

Publications (36) View all

• Article: Prevalence and European comparison of dementia in a ≥75-year-old composite population in Spain.

  J Virués-Ortega, J de Pedro-Cuesta, S Vega, M Seijo-Martínez, P Saz, F Rodríguez, A Rodríguez-Laso, R Reñé, S P de Las Heras, R Mateos, [......], J L Reglà, J Gascón, F J García, M Fernández-Martínez, R Boix, F Bermejo-Pareja, A Bergareche, F Sánchez-Sánchez, A de Arce, J L del Barrio
  [show abstract] [hide abstract]
  ABSTRACT: To estimate dementia prevalence in Spain. Nine probabilistic and geographically defined samples participated. A screening design based on the MMSE was implemented. Positively screened individuals underwent clinical evaluation. The total number of cases in Spain was estimated. Prevalence was confronted to that of other European countries. Five hundred and forty-six persons aged ≥75 participated, 49 had dementia (35 with Alzheimer's disease [AD], 10 with vascular dementia [VD], 4 other; 25 first diagnosed in the study). Age- and sex-adjusted prevalence and estimated nationwide cases were 7.5% (95% CI 5.4-9.7), 5.6 (95% CI 3.7-7.5) and 1.4 (95% CI 0.5-2.3), and 290,000 (95% CI 208,000-372,000), 214,000 (95% CI 141,000-288,000) and 54,000 (95% CI 20,000-88,000) for dementia, AD and VD, respectively. Dementia prevalence in Spain is comparable to other European populations, while a high number of undiagnosed cases live in the community. The potential impact of Mediterranean diet, hypertension control and decreasing vascular risk factors is discussed.
  Acta Neurologica Scandinavica 05/2011; 123(5):316-24. · 2.47 Impact Factor
• Article: Levodopa-induced dyskinesias in Parkinson disease are independent of the extent of striatal dopaminergic denervation: a pharmacological and SPECT study.

  Gurutz Linazasoro, Nadege Van Blercom, Alberto Bergaretxe, Fernández Manchola Iñaki, Enrique Laborda, José Angel Ruiz Ortega
  [show abstract] [hide abstract]
  ABSTRACT: The physiopathology of levodopa-induced dyskinesias (LIDs) is unclear. Presynaptic pharmacokinetic and postsynaptic pharmacodynamic mechanisms may be involved. We have analyzed several clinical and pharmacological parameters, as well as the status of the presynaptic dopamine nigrostriatal pathway by using DaTSCAN, in 14 patients with Parkinson disease who developed early and severe LID despite using low doses of levodopa and 10 patients without this complication despite the use of high levodopa doses. Patients were matched for age at onset, duration, and severity of Parkinson disease. Statistically significant differences were observed only in the duration of LID during the levodopa challenge. However, clear differences were also observed in weight and sex distribution (women with low weight predominate in the group with dyskinesia), severity and duration of LID, and total levodopa dosage. The pattern of response to levodopa and the uptake of (123I)N-w-fluoropropyl-2[beta]-carbomethoxy-3[beta]-(4-iodophenyl)nortropane were similar in both groups. These results indicate that the development of LID needs additional contributions beyond nigrostriatal denervation. Factors related to sex and body weight could play an important role. However, these findings should be considered cautiously because of the limited statistical power of the study.
  Clinical neuropharmacology 10/2009; 32(6):326-9. · 2.35 Impact Factor
• Article: [Neuroprotection in Parkinson's disease: analysis though group of experts' methodology].

  G Linazasoro, A Sesar, F Valldeoriola, Y Compta, M T Herrero, J C Martínez Castrillo, J J López Lozano, A Bergaretxe, L Vela, J M Fernández, [......], M J Catalán, P Mir, V Campos, F Grandas, A Mínguez, E Balaguer, R Yáñez, C Leiva, P García Ruiz, E Cubo
  [show abstract] [hide abstract]
  ABSTRACT: Currently used antiparkinsonian drugs neither stop nor slow-down the progressive nature of the disease. The final phase of PD is characterized by the presence of symptoms and signs resistant to dopaminergic agents, such as depression, dementia, freezing and falls. Therefore, it is urgent to develop therapies able to positively modify this outcome. Despite neuroprotection is a research priority in PD, no effective strategies have been found so far. A key informants study was conducted. A group of experts in PD fulfilled a questionnaire of 10 questions to explore the most important topics related to neuroprotection. Afterwards a consensus about the current situation of neuroprotection in PD was established and future directions of development were suggested. Most of the answers emphasized the need of new concepts, the limitations of animal models and the difficulties in the difficulties in demonstrating a neuroprotective effects in humans owing to a lack of biomarkers. Some of the experts believe that we are already exerting a disease modifying effect. The concept of neuroprotection should be widened. Animal models should be improved. A reliable biomarker to start neuroprotective therapies long before the appearance of motor symptoms and to evaluate the neuroprotective effect of any therapy should be urgently developed.
  Neurologia (Barcelona, Spain) 04/2009; 24(2):113-24. · 0.79 Impact Factor
• Article: Prevalence and European comparison of dementia in a ≥75‐year‐old composite population in Spain

  J. Virués-Ortega, J. de Pedro-Cuesta, S. Vega, M. Seijo-Martínez, P. Saz, F. Rodríguez, Á. Rodríguez-Laso, R. Reñé, S. P. de las Heras, R. Mateos, [......], J. Gascón, F. J. García, M. Fernández-Martínez, R. Boix, F. Bermejo-Pareja, A. Bergareche, F. Sánchez-Sánchez, A. de Arce, J. L. del Barrio, On behalf of the Spanish Epidemiological Studies on Ageing Group
  [show abstract] [hide abstract]
  ABSTRACT: Virués-Ortega J, de Pedro-Cuesta J, Vega S, Seijo-Martínez M, Saz P, Rodríguez F, Rodríguez-Laso Á, Reñé R, de las Heras SP, Mateos R, Martínez-Martín P, Mahillo-Fernández I, López-Pousa S, Lobo A, Reglà JL, Gascón J, García FJ, Fernández-Martínez M, Boix R, Bermejo-Pareja F, Bergareche A, Sánchez-Sánchez F, de Arce A, del Barrio JL; On behalf of the Spanish Epidemiological Studies on Ageing Group. Prevalence and European comparison of dementia in a ≥75-year-old composite population in Spain. Acta Neurol Scand: 2011: 123: 316–324. © 2010 John Wiley & Sons A/S.Objectives –  To estimate dementia prevalence in Spain.Materials and methods –  Nine probabilistic and geographically defined samples participated. A screening design based on the MMSE was implemented. Positively screened individuals underwent clinical evaluation. The total number of cases in Spain was estimated. Prevalence was confronted to that of other European countries.Results –  Five hundred and forty-six persons aged ≥75 participated, 49 had dementia (35 with Alzheimer’s disease [AD], 10 with vascular dementia [VD], 4 other; 25 first diagnosed in the study). Age- and sex-adjusted prevalence and estimated nationwide cases were 7.5% (95% CI 5.4–9.7), 5.6 (95% CI 3.7–7.5) and 1.4 (95% CI 0.5–2.3), and 290,000 (95% CI 208,000–372,000), 214,000 (95% CI 141,000–288,000) and 54,000 (95% CI 20,000–88,000) for dementia, AD and VD, respectively.Conclusions –  Dementia prevalence in Spain is comparable to other European populations, while a high number of undiagnosed cases live in the community. The potential impact of Mediterranean diet, hypertension control and decreasing vascular risk factors is discussed.
  Acta Neurologica Scandinavica 04/2011; 123(5):316 - 324. · 2.47 Impact Factor
• Article: "Frontotemporoparietal" dementia: clinical phenotype associated with the c.709-1G>A PGRN mutation.

  F Moreno, B Indakoetxea, M Barandiaran, A Alzualde, A Gabilondo, A Estanga, J Ruiz, M Ruibal, A Bergareche, J F Martí-Massó, A López de Munain
  [show abstract] [hide abstract]
  ABSTRACT: Mutations in the progranulin gene (PGRN) are a major cause of frontotemporal lobar degeneration with tau-negative and ubiquitin-positive neuronal inclusions. Most previous studies aimed at characterizing the clinical and neuropsychological phenotype of PGRN mutation carriers included patients with different PGRN mutations, assuming that the common proposed pathogenetic mechanism of haploinsufficiency will lead to a comparable phenotype. We studied 21 patients with a single pathogenic splicing mutation in the PGRN gene (c.709-1G>A) in the same tertiary referral center using homogenous diagnostic criteria and protocols. All patients were of Basque descent. Patients exhibited a variable phenotype both in age at onset and initial symptoms. Behavioral variant frontotemporal dementia (52.4%) and progressive nonfluent aphasia (23.8%) were the most common presenting syndromes. Apathy was the most common behavioral symptom. Patients developed a relatively rapidly progressive dementia with features that led to a secondary diagnosis in 61.9% of cases 2 years after primary diagnosis. Notably, this secondary or tertiary diagnosis was corticobasal syndrome in 47.6% of cases, which confirmed the neuropsychological features of parietal lobe dysfunction seen at the initial assessment in 81.8% of patients. Patients carrying the c.709-1G>A mutation in the PGRN gene showed heterogeneous clinical and neuropsychological features and commonly developed corticobasal syndrome as the disease progressed.
  Neurology 10/2009; 73(17):1367-74. · 8.31 Impact Factor